Bayer to Acquire Perfuse Therapeutics to Boost Ophthalmology Pipeline
Bayer to acquire Perfuse Therapeutics, strengthening its ophthalmology pipeline with a potential disease-modifying therapy for glaucoma and diabetic retinopathy.
Perfuse Therapeutics | 07/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy